arylsulfatase family member KGenealiases: MPS10 · TSULF
Q-omics provides the consensus-scored ARSK profile across patient tissues and cancer cell-line models. ARSK expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARSK is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, ARSK RNA expression shows 19,675 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, HNSC, and KIRP as cancer lineages where ARSK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARSK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARSK survival associations across molecular data types. ARSK RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARSK RNA expression–survival associations across cancer types. High ARSK expression shows unfavorable associations in MESO, LGG, LIHC, UVM and STAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARSK RNA expression.
This table summarizes ARSK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARSK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARSK shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher ARSK RNA expression in tumor versus normal tissue (log2 FC = +0.637, t-test p < 0.001).
This table shows molecular features associated with ARSK in patient tissues and cancer cell lines. In patient samples, ARSK shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ARSK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SKIN.
